90 related articles for article (PubMed ID: 31315351)
1. Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient.
Hecimovic A; Vukic Dugac A; Jankovic Makek M; Cikes M; Samarzija M; Jakopovic M
Monaldi Arch Chest Dis; 2019 May; 89(2):. PubMed ID: 31315351
[TBL] [Abstract][Full Text] [Related]
2. EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).
Ruiz-Patiño A; Castro CD; Ricaurte LM; Cardona AF; Rojas L; Zatarain-Barrón ZL; Wills B; Reguart N; Carranza H; Vargas C; Otero J; Corrales L; Martín C; Archila P; Rodriguez J; Avila J; Bravo M; Pino LE; Rosell R; Arrieta O;
Target Oncol; 2018 Oct; 13(5):621-629. PubMed ID: 30284706
[TBL] [Abstract][Full Text] [Related]
3. [Response of Erlotinib in Lung Adenocarcinoma Harboring EGFR Sensitive Mutation in Cerebrospinal Fluid: Case Report].
Li X; Yang H; Xu H; Wang S; Gao H
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):52-6. PubMed ID: 26805738
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
[TBL] [Abstract][Full Text] [Related]
5. Study of gefitinib maintenance in unselected patients with metastatic primary lung adenocarcinoma: A descriptive study.
Kumar R; Dubashi B; Kayal S; Lazzar SC; Barathi D; Kumar V
Indian J Cancer; 2017; 54(1):188-192. PubMed ID: 29199688
[TBL] [Abstract][Full Text] [Related]
6. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR-TKIs.
Masuda K; Tokito T; Azuma K; Yanagida E; Nakamura M; Naito Y; Matsuo N; Ishii H; Yamada K; Akiba J; Hoshino T
Thorac Cancer; 2018 Jun; 9(6):754-757. PubMed ID: 29675860
[TBL] [Abstract][Full Text] [Related]
8. Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation.
Erdogan B; Kodaz H; Karabulut S; Cinkaya A; Tozkir H; Tanriverdi O; Cabuk D; Hacioglu MB; Turkmen E; Hacibekiroglu I; Uzunoglu S; Cicin I
Bosn J Basic Med Sci; 2016 Nov; 16(4):280-285. PubMed ID: 27371767
[TBL] [Abstract][Full Text] [Related]
9. Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.
Fiala O; Pesek M; Finek J; Krakorova G; Benesova L; Minarik M
Tumori; 2014; 100(3):e70-3. PubMed ID: 25076254
[TBL] [Abstract][Full Text] [Related]
10. Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).
Cardona AF; Arrieta O; Zapata MI; Rojas L; Wills B; Reguart N; Karachaliou N; Carranza H; Vargas C; Otero J; Archila P; Martín C; Corrales L; Cuello M; Ortiz C; Pino LE; Rosell R; Zatarain-Barrón ZL;
Target Oncol; 2017 Aug; 12(4):513-523. PubMed ID: 28620690
[TBL] [Abstract][Full Text] [Related]
11. Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report.
Čoupková H; Vyzula R
Klin Onkol; 2018; 31(5):380-383. PubMed ID: 30541326
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
Kitade H; Yamada T; Igarashi S; Hokkoku K; Mori M; Shintaku K; Sagawa M; Nakai M; Yano S
Gan To Kagaku Ryoho; 2013 Jan; 40(1):79-81. PubMed ID: 23306923
[TBL] [Abstract][Full Text] [Related]
13. Severe megaloblastic anemia in a patient with advanced lung adenocarcinoma during treatment with erlotinib: a case report and literature review.
Yan X; Kong J; Wang J; Wang C; Shen H
BMC Pulm Med; 2024 Mar; 24(1):121. PubMed ID: 38448889
[TBL] [Abstract][Full Text] [Related]
14. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide DNA Methylation Analysis Reveals
Niu X; Liu F; Zhou Y; Zhou Z; Zhou D; Wang T; Li Z; Ye X; Yu Y; Weng X; Zhang H; Ye J; Liao M; Liu Y; Chen Z; Lu S
Clin Cancer Res; 2017 Sep; 23(17):5003-5014. PubMed ID: 28490462
[No Abstract] [Full Text] [Related]
16. [Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].
Caliez J; Monnet I; Pujals A; Rousseau-Bussac G; Jabot L; Boudjemaa A; Leroy K; Chouaid C
Rev Mal Respir; 2017 May; 34(5):576-580. PubMed ID: 27646667
[TBL] [Abstract][Full Text] [Related]
17. Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma.
He Y; Wang Y; Boyle T; Ren S; Chan D; Rivard C; Li X; Li J; Zhou C; Hirsch FR
Med Sci Monit; 2016 Jan; 22():276-83. PubMed ID: 26811313
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib.
Yokoyama A; Tamura A; Miyakawa K; Kusaka K; Shimada M; Hirose T; Matsui H; Kitani M; Hebisawa A; Ohta K
Intern Med; 2018 Aug; 57(16):2377-2382. PubMed ID: 29526950
[TBL] [Abstract][Full Text] [Related]
19. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
Sato M; Matsui A; Shimoyama Y; Omote N; Morise M; Hase T; Tanaka I; Suzuki K; Hasegawa Y
Intern Med; 2018 Dec; 57(23):3429-3432. PubMed ID: 30101911
[TBL] [Abstract][Full Text] [Related]
20. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
